Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : All Clowns Must Be Destroyed -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (33576)	5/18/2000 12:45:00 PM
From: Ilaine	Read Replies (1) \| Respond to of 42523

Not sure what you mean about the US Patent office disagreeing with me. Celera has no patents on the gene sequence issued as yet. Zero, zip, niente, nada, rien. At least that's what a boolean search of the US patent office reveals, maybe you've got newer information? uspto.gov The Human Genome Project, run in part by NIH, is going deeper (more detail) into sequencing the human genome, but Celera is faster. They published the gene sequence of Drosophila last month in Science.

To: LLCF who wrote (33576)	5/18/2000 1:55:00 PM
From: Ilaine	Respond to of 42523

BTW, the phone rang before I had a chance to edit my last post. Agree with your points about the information being important, and that significant money can be made by licensing the information and collecting royalties. My points were solely directed to the patent issue, not to the value of the research. Obviously, if Pfizer or Merck can develop a treatment based on the research, that's patentable. I have rheumatoid arthritis, which has a genetic component, so I have a personal interest in new treatments.